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Abstract In publicly funded health care systems, decision
makers must continually balance often conflicting priorities
of efficiency and equity. Health economists have developed
a set of highly sophisticated analytical methods for
assessing efficiency, but less attention has been paid to
formally incorporating equity considerations into analyses.
As a result, where equity is considered is often informal, ad
hoc and/or simplistic. This paper is a proposal for a
mechanism for formally incorporating equity within the
decision process. It begins with an overview of the current
literature on equity weighting. It then considers the case of
a single equity domain and illustrates how this is currently
applied in practice by the UK’s National Institute for
Health and Care Excellence. It then proposes a more
comprehensive method for considering the multi-attribute
equity state, where a population exhibits more than one
trait considered worthy of differential weighting. Finally,
the paper proposes a mechanism by which this could be
applied in practice, and concludes with a discussion of the
challenges for applying multi-attribute equity weighting.
Keywords Equity  Equity weights  Distributional
weights  Cost-effectiveness
JEL Classification I1 Health  I10 General  I14 Health
and Inequality  I18 Government Policy, Regulation, Public
Health  I19 Other
Introduction
Those tasked with allocating scarce health care resources in
publicly funded health care systems are required to balance
often conflicting aims of efficiency and equity. Health
economists have developed a set of highly sophisticated
analytical methods for assessing efficiency, but less atten-
tion has been paid to formally incorporating equity con-
siderations into analyses. As a result, where equity is
considered, the process is often informal, ad hoc, simplistic
and lacking in transparency. The most commonly recom-
mended approach for considering equity in the decision
making process is the application of an equity (or distri-
butional) weight [1, 2], though to date no decision making
bodies have formally adopted such an explicit approach.
Yet some decision making bodies acknowledge that they
do think about weighting criteria, even if this is not typi-
cally done explicitly or through formal methods. While
occasionally equity weighting is explicit in individual
decision processes, it is often implicit and revealed only
through the decisions themselves [3]. And while many
countries make reference to equity related issues in the
technical guidance used to guide decision makers [4], these
are frequently specified in terms of deliberative processes
for considering equity concerns or relate to consideration
of clinical sub-groups. But, as has been argued elsewhere
[5], the complexity of considering equity in a deliberative
process is staggering. To do so in a transparent way, that
meets the standards required of procedural justice, is nigh
on impossible. A current challenge for the research
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community is therefore how (or even whether) QALYs
should be weighted across different categories of individ-
uals in order to address concerns of equity in resource
allocation decisions.
There are numerous difficulties that arise in trying to
estimate and apply equity weights, and Wailoo et al. [6]
highlight many of these. Perhaps the most challenging
problem is that patient populations, even when sharing the
same illness, are heterogeneous in many other respects, and
are therefore likely to be possessed of many different
attributes that might be considered worthy of equity
weighting. To deal with the challenges of the population
that exhibits multiple equity relevant attributes, this paper
draws on recent literature to propose a formal mechanism
for incorporating multiple equity-related attributes within
the decision process—the multi-attribute equity state
(MAES).
The paper begins with an overview of the current lit-
erature on equity weighting. Consideration is then given to
the simple case of a single equity domain in order to
illustrate how equity weights are currently applied in
practice by the UK’s National Institute for Health and Care
Excellence (NICE). A proposal is then outlined for a more
comprehensive formal method for considering equity
weighting in populations that exhibit more than one trait
considered worthy of differential weighting. The paper
concludes with a discussion of the challenges for applying
multi-attribute equity weighting. It is not the aim of this
paper to consider the arguments about whether ‘a QALY is
a QALY’—this has been done elsewhere (for some
examples of this literature, see McCabe et al. [5], Round
[7], Donaldson et al. [8] and Dolan et al. [9]). Irrespective
of the view one takes on the principle of differential
weighting of QALYs, in practice it is becoming more
common—in the UK alone, differential weights have been
applied to treatments for those at the end of life [10], for
those with cancer [11], for childhood vaccines [12], and for
very rare diseases [13]. Rather, this paper is concerned with
principles of procedural justice—if differential weighting
is to be undertaken, it should be done in a manner that is
fair, transparent, and has democratic legitimacy.
Equity weights in economic evaluation
For many, the notion that ‘a QALY is a QALY’ is a fun-
damental principle of resource allocation decision making
and cost-utility analysis [7, 14]. While this principle is
widely assumed in the practice of economic evaluation, it
is not universally accepted. It has been suggested by some
that there are occasions when differential consideration
should be given to health gains (or other benefits of treat-
ment) based on the characteristics of those receiving care.
It has been argued, for example, that the principle of equal
value for all QALY gains is disadvantageous to people at
the end of life [15, 16], that it is ageist [17, 18] and that it is
based on assumptions about the characteristics of individ-
uals that do not hold [19–21]. As a result, a literature has
developed on how it might be possible to give greater
weight, and therefore greater access to scarce resources, to
some populations over others. Such weights are variously
referred to as distributional weights or equity weights,
referring to the idea that, by weighting health gain, a more
equitable distribution of health can be achieved relative to
the dominant health maximisation approach implied in the
acceptance of the idea that ‘a QALY is a QALY’.
An overview of the current literature
Much of the literature on equity weighting is concerned
with the identification of attributes for weighting or esti-
mating weights for individual attributes. A review from
Paulden et al. [22] identified 19 individual candidate
attributes for weighting from the existing literature. And in
recent years, a number of empirical studies on equity
weights and distributional concerns have been published. A
recent systematic review [2] identified 64 such studies,
published between 1989 and 2014. All studies included in
that review reported on the identification of attributes
deemed to be important in weighting, from a range of
different populations (most commonly the UK, US and
Australia). Studies included in the review were mixed as to
whether they focused on a single attribute (28 studies) or
multiple attributes (36 studies). A minority (22 studies)
also attempted to estimate distributional weights for the
identified attributes. Of these, 19 studies estimated weights
for single attributes, and three studies [23–25] that esti-
mated weights for multiple attributes (and of these, two are
based on the same research into the social value of the
QALY [23, 24]). Research that focuses on the existence of
preferences between characteristics is also ongoing [26].
The Social Value of a QALY (SVQ) research project
[23, 24] estimated weights using two different methods—a
discrete choice experiment (DCE) and a person trade-off
exercise (PTO). This research found that irrespective of the
method by which weights were derived, people expressed a
preference for health gains that are accrued by young
people or the elderly. Only one attribute apart from age was
considered to be important in health distribution; using the
PTO method (but not in the DCE), it was found that illness
severity should be given consideration.
The other study identified by Gu et al. [2] to estimate
multi-attribute weights is from Dolan and Tsuchiya [25],
who examined the trade-off between maximising total
health gain against reducing inequalities in health. In this
study, weights were estimated through trying to estimate a
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social-welfare function, incorporating equity considera-
tions. They showed that a sample of the general public
gave greater weight to health gain when a person was
expected to die at the age of 60 compared to someone
expected to die at the age of 70. They also found that the
less time a person spent in full health, the greater the
weight the respondents gave to gains in health. The overall
results from this study suggest that age at death, and the
length of time lived in good health, are both important
priorities for equity weighting among the general public.
The most recent study to consider equity weighting is
from Rowen and colleagues [3], and was undertaken as part
of a programme of work looking at value-based pricing in
decision making [27]. This study focused on whether
greater value should be placed on populations according to
the burden of illness they experience (which might other-
wise be described as severity) and/or whether they are end-
of-life. The results of this work found that both the
‘severity’ and ‘end-of-life’ were considered important
considerations for weighting in decision making. This
study was limited by design to considering burden of ill-
ness and end-of-life as potential equity weights.
TheSVQwork represents themost comprehensive effort to
date to understand the effects of multiple equity attributes on
public preferences for health gain. While this work did iden-
tify a small number of instances where health gains would be
differently valued by the public,most of the estimatedweights
were small [23]. By contrast, Dolan and Tsuchiya found rel-
atively large weights applied to differences in the age of the
beneficiary at onset and at death [25]. One possible reason for
the discrepancy between the two studies is the number of
attributes that respondents were asked to consider. In the SVQ
project, respondents were asked to consider attributes relating
to age at death, age at onset of ill-health, the severity of health
lost and the potential health gain from treatment. Dolan and
Tsuchiya [25] only required respondents to consider the age at
death and age of onset of ill-health. This supports the idea that
there are important interactions to be considered in developing
equity weights.
Another possible source of difference in the two sets of
results is the approach used to estimate weights. Dolan and
Tsuchiya [25] used an approach based on trying to identify
a latent social welfare function based on the stated pref-
erences of individuals. The SVQ project team undertook a
discrete choice experiment [23] and person-trade-off
exercise [24]. Given differences in the underlying con-
ceptual basis of each method, it is possible that this would
lead to different weights being obtained. If the difference in
results is down to the empirical method selected, then the
wide variation in estimated weights should raise concerns
about the validity of any results obtained to date. Further
research into the most appropriate methods of deriving
weights should be considered a priority.
Equity weighting in current practice
As highlighted above, although much research has been
done to derive individual or joint weights for equity attri-
butes, there is no accepted formal system for applying
weights in economic evaluations. Yet, despite this,
weighting is routinely done, both implicitly [28] and
explicitly [12], in the practice of decision making. This
creates obvious problems. Such an approach lacks trans-
parency, leads to a simplistic consideration of equity and is
likely to result in a series of inconsistent, ad hoc decisions.
The end-of-life criteria as applied by NICE are an ideal
example of the flawed current process.
Box 1. NICE end-of-life criteria
The treatment is indicated for patients with a short life expectancy,
normally less than 24 months and;
There is sufficient evidence to indicate that the treatment offers an
extension to life, normally of at least an additional 3 months,
compared to current NHS treatment, and;
The treatment is licensed or otherwise indicated, for small patient
populations
In 2009, NICE introduced a series of criteria that would
apply to cost-effectiveness decision making processes for a
small subset of treatments, in a subset of patients (see
Box 1). The rationale for this was that this patient group
was somehow disadvantaged by the existing systems and
did not receive an equitable allocation of resources. The
practical effect of this policy has been to introduce a dis-
tributional weight for allocating resources when consider-
ing a particular population. Under the revised scheme,
treatments meeting the new end-of-life criteria could be
approved for use in the NHS under a less stringent
threshold for cost-effectiveness than required for other
treatments. Now, instead of being required to provide an
additional QALY at a cost of £20,000 to £30,000, quali-
fying treatments must only generate each additional QALY
at an incremental cost estimated to be in the region of
£50,000 [29].
In effect this policy has created the first explicit equity
weight to be used in practice by NICE—if the end-of-life
threshold is in fact £50,000/QALY, then it is 2.5 times that
of the lower limit of the standard threshold. If the threshold
is taken to represent the opportunity cost of health dis-
placed, this gives some sense of how much more weight
decision makers place on the QALYs that accrue to the
beneficiaries of the policy.
The approach chosen by NICE in relation to end-of-life
treatments cannot be justified by equity concerns. Paulden
and colleagues [30] have shown that simply applying a
differential threshold to treatments or populations fails to
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identify who bears the opportunity cost of the additional
weight given to the beneficiaries’ health. Where the
patients who bear the opportunity cost of the decision are
similar to those who gain, this can lead to differential
weights being applied to similar patients, a violation of the
principle of horizontal equity. The argument of Paulden
et al. [30] is summarised as follows.
Consider a new treatment for a specific illness, where
the opportunity cost is borne solely by other patients who
also have that illness. Suppose that, for every £20,000 spent
on the new treatment, one QALY is displaced among those
patients who bear the opportunity cost. A healthcare payer
wishes to assign 2.59 the value to QALYs for patients
with the illness in question, and so decides to assign an
acceptable threshold of £50,000 per QALY (2.59 the
standard threshold of £20,000 per QALY). However,
treatments approved at this threshold would displace 2.5
QALYs among patients who bear the opportunity cost—
who in this example all have the same illness as the ben-
eficiaries of the new treatment. The payer would be
choosing to displace 2.5 QALYs in order to fund a treat-
ment that generates just 1 QALY among patients with an
identical illness. In this case, it would be more equitable to
retain the original threshold. The revised threshold is only
suitable where those who bear the opportunity cost have no
overlap with the beneficiaries of treatment. Of course, in
practice it might be unlikely that all patients who bear the
opportunity cost have an identical illness to the beneficia-
ries—more likely, we would expect that the group of
patients that bears the opportunity cost contains some with
the illness in question (who should receive the same special
consideration as the beneficiaries of the new treatment) and
other patients who do not. This implies that the correct
threshold should be somewhere between £20,000 and
£50,000, depending upon the prevalence of the illness in
question among the patients who bear the opportunity cost.
This prevalence would only be revealed if the make-up of
the opportunity cost group is known. For a full discussion
see Paulden et al. [30].
In addition, the introduction of this equity weighting
system has been undertaken with little regard to the
methodological literature on applying equity criteria to
economic evaluations. The Gu et al. review [2] identified
seven studies that considered whether people value end-of-
life differently in terms of distributional effects. Five of
these studies found little to no evidence that this was the
case. And among those studies that did find end-of-life to
be an important criterion, only one attempted to estimate a
distributional weight [31]. Pinto-Prades et al. estimate that
the societal value of a QALY for a person at the end of life
is 1.41 times greater than for others [31]. In the UK context
and using a baseline threshold of £20,000/QALY, this
would imply a threshold of £28,200 per QALY, lower even
than the upper limit of the standard threshold, suggesting
no need for specific criteria.
Multi-attribute equity considerations
As illustrated in the Gu et al. review [2], it is feasible and
relatively straightforward to estimate equity weights for
single attributes. However, it is unrealistic to believe that
those concerned with equity in provision of treatments are
concerned only with single-attribute populations. It is far
more likely that decision makers will be routinely con-
cerned with multi-attribute populations in allocation deci-
sions. For example, it is common for public discourse to
suggest that both children and those at the end of life
deserve exceptional consideration [12, 28], a clear example
of a multi-attribute scenario.
It is also straightforward to apply single attribute weights
in practice (assuming that, unlike the end-of-life criteria,
they are evidence based). One possibility is that the weight
could simply be applied directly to the QALY estimates
used in the calculation of the cost-effectiveness ratio,
thereby changing the ICER. Another approach, as taken by
NICE, would be to apply a differential threshold criterion
[10]—though it should be noted that these approaches may
lead to different decisions and so should not be considered
equivalent. For example, an intervention that is ‘dominated’
(i.e. more expensive and less effective than a comparator)
without a weight applied may no longer appear dominated
(and may even appear cost-effective) when the weight is
applied. If, instead, the threshold is altered as an alternative
to applying weights, then the dominated intervention will
always appear dominated and so cannot appear cost-effec-
tive, irrespective of where the threshold is set [30]. It should
also be borne in mind that while the end-of-life criteria may
be weighted positively, weights may also be negative,
reflecting attributes disfavoured by the public.
It is more difficult to deal with the multi-attribute sce-
nario, and there are important methodological issues raised
in a situation where there is a conjoint distributional
problem. The most immediate solution to the problem
would be to apply each weight individually in sequence.
This approach works if it is assumed that weights are
independent from one another and can be combined mul-
tiplicatively. Distributional weights estimated for individ-
ual attributes could then be applied, with no limit on the
number of attributes considered. For the end-of-life child,
the calculation is simply:
Incremental cost
(Incremental QALY  WeightEndofLife  WeightChild)
It is unlikely, however, that equity weights associated
with individual attributes are independent of one another.
J. Round, M. Paulden
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What is more likely is that the jointly estimated distribu-
tional weight (hereafter the joint-weight) is different from
the product of the independently estimated weights. There
is no conceptual basis on which to predict whether the
joint-weight applied to the end-of-life child is greater than,
less than, or equal to the product of the independently
estimated weights. This can only be determined empiri-
cally. The Gu et al. review [2] highlighted the need for
additional research on dealing with this joint distributional
problem. In the UK, NICE proposed a maximum threshold
of £50,000 per QALY when considering joint weights,
although, as Paulden et al. show, this could lead to logi-
cally inconsistent decision making [30].
Multi-attribute equity states
The following is a proposed solution to the challenge of
incorporating multiple equity concerns within the decision
making framework—the multi-attribute equity state
(MAES). The framework for this system is guided by the
recommendations of McCabe et al. [5]. It is illustrated in
brief in Fig. 1. Nominally in reference to NICE’s end-of-
life premium, McCabe et al. identify a set of criteria that
any system that applies differential value to health gains
must satisfy in order to be considered equitable. These are
summarised in Table 1. As will be demonstrated, the pro-
posed MAES framework satisfies the McCabe et al. crite-
ria. In some respects, the proposed MAES is not new—a
similar concept has been applied elsewhere in practice
[24], though that discussion did not formalise the criteria
for developing a comprehensive and consistent system that
could be applied in a decision making context. It also did
not address all of the criteria later set out by McCabe et al.
[5].
The MAES framework is broadly analogous to the
multi-attribute health state (MAHS) approach, as used to
estimate utility values. Each approach has a reference
value, is defined by a series of attributes and levels, and
leads to the estimation of a weight applied to the health of
the beneficiary of the health gain within the decision
making process. In this section, further details are provided
on the conceptual framework of the MAES, with particular
reference to the MAHS classification approaches. The
framework is also related throughout to the McCabe et al.
[5] criteria described above. The next section discusses the
MAES as it might be applied in practice.
The reference standard
When estimating health state utility values the reference
standard is full health—this is ascribed a maximum value
of 1, on a scale typically anchored at 0 (representing the
state of being dead). In the standard model, health states are
then defined by a multi-attribute classification system, such
as the EQ-5D [32]. Once defined, these states are then
weighted according to a perceived deviation from the state
of being in full health. In the EQ-5D classification and
weighting system, the state defined by 11,111 is weighted
as 1, meaning a year spent in that state is a year spent in
Fig. 1 Proposed operational model of the multi-attribute equity state (MAES) approach
Table 1 McCabe et al. criteria for equity weighting schemes
Criteria Description
1 No single attribute should attract a value premium in isolation
2 Effects on those who bear the opportunity cost must be explicitly considered, not just benefits to the identified populations
3 Definitions for individual criteria must be validated against societal preferences
4 Weights must be applied equally to benefits in both quality and quantity of life
5 Weights must be empirically derived
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full health. The state 22,222 describes a state of reduced
health in all domains and is given a weight of 0.516
according to the UK EQ-5D-3L tariff [33], meaning a year
lived in that state is the equivalent of roughly just half a
year in full health.
To apply a system of multi-attribute equity states, a
similar reference standard is needed. Unlike with health
states, where the reference standard is full health, there is
no obvious candidate for what the reference equity stan-
dard should be. One possibility is to anchor the system at 1
and 0, as with health states. In this approach, a weight of 1
applies where the population has a set of characteristics
such that the net effect of these on the value of additional
QALYs cancels out entirely (i.e. the same value is placed
on additional QALYs for such individuals whether or not
the additional weights are applied). A weight of 0 then
applies when, given their characteristics, society places no
value on additional QALYs for a patient or population. The
system is bound by 0 at the lower end, but has no maxi-
mum positive weight. The proposal here is that the refer-
ence standard for a MAES is the case where the individual
or population does not possess any particular characteris-
tics considered to be deemed worthy of consideration for
equity adjustments.
Defining attributes
Defining the reference standard will require considerable
investigation as to which attributes were deemed important
to a population. This could be done through reference to
the existing literature, as in the review from Paulden et al.
[22] or through public surveys or focus groups, as per
Baker et al. [24]. Public policy documents might also
reveal attributes that are deemed relevant by decision
makers. However, to maintain public support and to meet
the demands of procedural justice (criterion 3, Table 1),
any system for identifying equity attributes must at some
stage be subject to public debate, be it through a process
such as the NICE Citizen’s Council or through extensive
empirical work and qualitative research with the general
public. In addition, it must be recognised that the prefer-
ence for attributes may change over time, as population
norms and preferences change, and that this may require
periodic updating of the MAES descriptive system and
subsequently the MAES valuation set.
There are immediate difficulties apparent in trying to
select attributes. Everyone has a race, sex and age, so
defining which of these, if any, becomes part of the ref-
erence case is not straightforward. Should we include race/
ethnicity as part of the reference case? Some illnesses are
more prevalent in certain ethnic groups than in others and
so this may be relevant. What about sex? And if we include
sex, how should we consider inter-sexed people, or those
who identify as a gender other than one assigned at birth?
Would including these characteristics work to decrease
disparities in health outcomes accordingly? We must also
ask if the inclusion of certain characteristics would be in
contravention of local or regional laws or institutional
policies. In the UK, NICE is guided in incorporating equity
considerations by both its own Social Values Judgment
policy as well as anti-discrimination legislation [34].
Application of a MAES that violated these existing criteria
could lead to a violation of procedural justice, and could be
illegal.
Defining the reference group is clearly difficult, though
it should be possible. However, it cannot be done in a
single essay and no particular classification system is
proposed here, rather a principle by which to establish one
in future. To determine the reference case will require
considerable research effort and public debate. A multi-
attribute reference case derived from public preferences
satisfies the first and third criteria identified in Table 1.
Equity state classification system
The first step to determining the classification system is to
determine what attributes it should contain, as discussed
above. Once this has been done, it then must be decided
how these attributes should be described within the clas-
sification system, similar to the way different levels of
health attributes in MAHS classification system are
described. For example, if age is selected as an attribute, it
is possible to define it in the classification system in a
multitude of ways. We may for instance include children,
working age adults and adults older than the retirement
age. Or we may class age in relation to the age at the onset
of an illness. Or we may class age according to multiple
such criteria. As with the attributes themselves, selecting
the set of attributes must be done with reference to societal
preferences, as any system of equity weighting that does
not receive public support will be open to challenge on
issues of procedural justice.
Once the attributes and levels have been selected, these
combine to create a classification system, similar to a
multi-attribute health state classification system. The clas-
sification system describes the complete set of equity-states
that will then be used in the formal process of equity
weighting. One possible approach for developing the
overall classification system is for wider public consulta-
tion on the attributes of interest, with the operationalising
of the attributes in the form of the classification system left
to the research and policy community. Turning broad
concepts such as age or illness severity into operational
constructs is a complex and challenging endeavour
requiring specialist skills. However, to maintain public
input, the final classification system could be presented to
J. Round, M. Paulden
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the public for further consultation and refinement. This
approach has been used in the development of MAHS
classification systems [35].
Weighting (or valuing) the MAES
Given an equity state classification system, it then becomes
possible to rank and weight each state. Ranking can be
undertaken using similar principles to the ranking of health
states. Defining the equity state classification system defines
the reference case and it is assigned a weight of 1.0. Other
equity states are ranked andweighted relative to the reference
case. The theoretical minimum value for an equity weight is
0, meaning that no resources would be allocated to that
population despite any potential health gains. There is no
maximum theoretical value. Equity weights can then be
determined by public assessment of the various combinations
of the possible equity states using choice based methods.
Previous attempts to estimate multi-attribute weights
have used discrete choice experiments [3, 23], person-
trade-off methods [24] and a social welfare function
approach [25]. The most common approach to estimating
weights for single attributes as described in the Gu et al. [2]
review was the person-trade-off method. The results of the
different attempts to estimate multi-attribute weights sug-
gest that the method employed can lead to differing results,
though this is confounded by the fact that each study was
estimating weights for slightly different sets of attributes,
classified in slightly different ways from one another. It is
not clear from the small number of studies estimating
weights for multiple attributes which method is best; in
fact, it is not even clear how to define ‘best’.
It is important therefore that a set of conditions to
determine which valuation method is most appropriate
must be established a priori. As part of the SVQ project,
Baker et al. undertook both a PTO and DCE, and each gave
different results [24]. They concluded that ‘‘…the extent to
which either approach yields results that are entirely con-
sistent with social preferences is uncertain.’’ (Baker et al.,
p. 68, [36]). Not establishing a priori the grounds for
choosing between different approaches risks, like Baker
et al. [24], finding a range of different outcomes across
different methods, with no means of choosing between
them. It may be that multiple valuation methods are equally
justifiable. If this is the case, clear decision criteria for
choosing between the results of all methods should be
stated at the outset of the study. In future, researchers may
wish to register their research protocols with online
repositories to illustrate what they plan to do ahead of
doing it, reducing the risk of results being questioned later.
The criteria outlined below are necessary conditions for
valuation studies of equity states:
1. The method must be choice based or ranking based.
Respondents must be required to evaluate different
alternatives and express preferences for options across
the whole set of alternatives.
2. The task must not be cognitively demanding. Respon-
dents must be able to understand easily what they are
being asked to do. Cognitively demanding tasks risk
respondents providing unreliable answers or not com-
pleting the whole task [24].
3. The task must be feasible. Some methods may require
the valuation of large numbers of states, leading to
non-completion by participants. Larger sample sizes
valuing smaller numbers of states may facilitate this,
but will then likely require online completion. A
method that requires an unrealistic sample size will not
be suitable.
4. The method and sample size must be appropriate for
dealing with interactions between individual attributes.
Given the current state of the art, the most likely can-
didates to meet the above criteria are best-worst scaling
approaches and discrete choice experiments. If a decision is
made to undertake two different valuation exercises (for
example, see Baker et al. [24] or Coast et al. [37]) there
should be established conditions for choosing between each
method. In choosing between two sets of results, one might
consider whether one method generates a more consistent
set of estimates [37], the reliability of the method (if the
same experiment is run in a new population, are the results
consistent?) or whether one method gives nonsensical
results (e.g. equity weights of less than 0). Ranking and
choice based methods satisfy the McCabe et al. criterion
five, as listed in Table 1.
Applying the MAES
Once the equity states have been ranked and valued, the
weights can be applied in decision making. One obvious
approach to doing so is to apply the weights to the utility
values estimated for the patient population and used to
calculate QALYs. If the population being considered is the
reference case, then the utility value is simply multiplied
by 1—effectively no equity weighting is applied. If the
population differs in some characteristic from the reference
population then the relevant equity weight is applied
according to the ranking of that state. The process for this
is simple—one just looks up the value corresponding to the
equity state and applies that to the utility score. This
adjusted utility value is then used in the QALY calculation
in the standard way. This satisfies the 4th McCabe et al.
criterion: that weights apply to both quality of life and
length of life.
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The most challenging component of this process is
outlined by McCabe et al. [5] and concerns the role of the
population from whom disinvestment in health is being
made to fund the new treatment. Any allocation of
resources results in an opportunity cost—those resources
cannot be used to treat anyone else. When allocating
resources, we typically know the identity of those receiving
the treatment under consideration. However, we do not
typically know the identities of those patients for whom
treatment must be withdrawn. In the case where ‘a QALY
is a QALY’ across all populations, then accounting for the
opportunity cost simply requires estimating the health
forgone, regardless of the identity and characteristics of
those patients affected. A cost per QALY threshold, such
as that estimated by Claxton et al. [38], is all that decision
makers need to consider. However, if a QALY is not
always QALY, then a cost per QALY threshold is insuf-
ficient. We need to know not only how many QALYs are
displaced, but also the characteristics of those patients who
lose QALYs, so we can apply weights to these QALYs
accordingly.
Calculating gains and losses
To estimate the gains and losses we need to consider the
patients to whom those gains and losses apply. We identify
four distinct sets of QALY gains and losses to consider:
• Qge = QALYs gained by those with special
characteristics
• Qgn = QALYs gained by other patients (those with no
special characteristics)
• Qde = QALYs displaced in those with special
characteristics
• Qdn = QALYs displaced in other patients
The total QALYs gained are:
Qg ¼ Qge þ Qgn ð1Þ
The total QALYs displaced are:
Qd ¼ Qde þ Qdn ð2Þ
In the case where a ‘QALY = QALY’, then a technol-
ogy is cost-effective if:
Qg[Qd ð3Þ
In the weighted QALY calculation, if an intervention is
favoured only after weighting, then by definition the
unweighted QALYs gained will be less than the
unweighted QALYs displaced. In the scenario where the
populations gaining and losing QALYs are entirely distinct
from one another according to the MAES, then the calcu-
lation is simple, applying equity weight k to Eq. (3)
:
Qd\Qg  k ð4Þ
But this only necessarily holds if the disinvestment
population is distinctly different from the intervention
population across all equity criteria in the MAES. If the
group from whom QALYs are disinvested also includes
individuals who have the equity attribute(s) under consid-
eration, this changes the number of unweighted QALYs
required in the equity-favoured group in order for the
intervention to be considered cost-effective. Where k is
applied to the QALYs of patients with special character-
istics only, then the weighted QALYs gained are:
Q^g ¼ Qge  k
 þ Qgn ð5Þ
The weighted QALYs displaced are:
Q^d ¼ Qde  kð Þ þ Qdn ð6Þ
And a technology is cost-effective if:
Q^g[ Q^d ð7Þ
Alternatively, this could be expressed as:
k  Qge  Qde
 þ Qgn  Qdn
 
[ 0 ð8Þ
Identifying the proportion of people that may be in both
the equity-favoured group and the displaced-care group
may be difficult (and in some cases not possible). We
typically do not know in a standard cost-effective analysis
which groups stand to lose care as a result of an allocation
decision, irrespective of weighting. The addition of an
equity weight does not necessarily change this. If anything,
it makes it more difficult—with equity weighting it will be
necessary to identify exact sub-groups (and their size) for
whom care is displaced in order to estimate Q^d. This does
not mean an equity weighting system should not be con-
sidered, but that the burden on analysts to identify those
who bear the opportunity cost may be significant. An
example of how the MAES would be applied in practice is
provided in the online supplementary material.
Can the MAES work in practice?
A system of equity weighting based on MAES, as outlined
above, can work in principle. Conceptually, it is straight-
forward. It would require significant development and
empirical work, but this would be little different, in prin-
ciple, to the work that has underpinned the development of
the cost-utility framework widely used in practice today. In
addition, unlike the approaches applied by NICE in the
end-of-life criteria [10], or the Joint Committee on Vac-
cination and Immunisation [12], the MAES can, in prin-
ciple, satisfy the McCabe et al. criteria while not violating
norms of procedural justice or horizontal equity.
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The means of undertaking such research are becoming
more accessible to researchers. While a MAES might
represent a more technically complex problem than health
state valuations in terms of ranking and weighting tasks,
choice-based experimental methods are continuously being
developed and refined, providing tools unavailable to those
who first developed utility weights. It is not impossible to
imagine a MAES tariff similar to that of the EQ-5D being
developed. The SVQ project was such an attempt, and
provides valuable insights in how to undertake further
work. In addition, online survey technology is such that
large samples of the population can be accessed to under-
take DCEs or ‘best-worst scaling’ experiments. While there
are arguments about the validity of online samples, steps
can be taken to minimise the risks of bias [1]. In any case,
any such risks must be weighed against the enormous cost
in time and money that would be required to achieve an
adequate sample size in face-to-face interviews. It is
legitimate to ask whether an imperfect evidence base
applied transparently is better than current systems, where
little empirical evidence is applied and decisions are made
deliberatively.
The construction of the MAES descriptive system, and
the ranking and valuation of the resulting states, will pre-
sent challenges to researchers. But these will not be the
most difficult problem in the implementation of an equity
weighting system. The greatest challenge will be estimat-
ing the values to assign to estimate the total burden of
health displaced owing to weighting. Without including
these values in the overall estimate, it is not possible to
fairly assess the impact of weighting on those who bear the
opportunity cost. But, as has been described above, it is not
usually possible to identify specific groups from whom care
will be withdrawn in order to invest elsewhere. Finding a
solution to this particular challenge seems to be the most
pressing research question relating to equity weighting. A
system that applies equity weights to one population
without accounting for those who lose out will not be fair
or transparent, and seems unlikely to be able to maintain
public favour over time.
Equity: horizontal or vertical?
That a QALY is a QALY is a specific vertical equity
position, and one with which many are uncomfortable.
There are also many reasonable alternative vertical equity
positions where a QALY is not always a QALY. However,
regardless of the vertical equity position adopted, it
remains important to respect the principle of horizontal
equity—treating individuals with similar characteristics in
a similar way. Applying ‘equity’ weights only to the
(identifiable) beneficiaries of a treatment, and not to the
(similar but unidentifiable) bearers of the opportunity cost,
violates this principle of horizontal equity [39]. This leaves
the options of
1. Retaining the status quo, with all QALYs being equal,
which maintains horizontal equity (by definition) but
adopts a contentious vertical equity position, or
2. Moving to an alternative (and arguably more accept-
able) vertical equity position but applying it in such a
way that violates horizontal equity. The challenge here
is to identify what level of horizontal inequity is
acceptable, and justifying where the burden of that
inequity should fall.
In an ideal world, we would satisfy both horizontal and
vertical equity in a framework where a QALY is not
always a QALY, but as identified above, this requires in-
depth knowledge of the characteristics of the bearers of the
opportunity cost (which might differ for each intervention
and may not be possible to estimate) and a willingness to
apply weights consistently across both the ‘winners’ and
‘losers’ such that horizontal equity is maintained, regard-
less of the vertical equity position adopted.
Conclusion
Whether or not one agrees that equity weighting is
appropriate in allocation decisions, it happens in practice
and this is unlikely to change. It is therefore essential that
equity concerns are incorporated into the decision making
process in a way that is transparent, fair and conforms to
standards of procedural justice. In the UK, the present
system resoundingly fails to meet such standards—neither
the end-of-life criteria nor the Cancer Drugs Fund meet a
single criterion as set out by McCabe et al. [5]. The
legitimacy of a system by which certain populations are
favoured over others in resource allocation decisions rests
solely on its acceptance to the public, for which the per-
ception of transparency and fairness will be critical. The
development of a conceptual framework for the incorpo-
ration of equity weighting into cost-utility analysis, as
described above, is an important component of achieving
these aims of transparency and fairness.
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